Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05384847 · ClinicalTrials.gov registry record · Phase 1

Effects of Triiodothyronine (T3) in Ischemic Heart Failure

A Phase 1 study of Heart Failure, sponsored by Emory University.

Active
Registry status
Phase 1
Development phase
20
Enrollment target
2
Study locations

NCT05384847 is a Phase 1 study of Heart Failure that is active but no longer recruiting, run by Emory University. The registered enrollment target is 20 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05384847, a Phase 1 study of Heart Failure, is active but no longer recruiting, sponsored by Emory University.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
20 participants
Enrollment target
2
Study locations

Study Summary

This study aims to determine whether giving triiodothyronine (T3), a thyroid hormone, is safe and helps improve symptoms and signs of heart failure. The study is divided into 2 phases. In the first phase, participants have a 50-50 chance of receiving the study drug. Participants who are enrolled to receive the study drug will be admitted to the General Clinical Research Center (GCRC) for 5 days for oral thyroid hormone treatment and monitoring. They will have 4 additional follow-up visits over the next year. Participants who are not enrolled to receive the study drug will not be admitted but will have similar follow-up visits in the outpatient setting. Participants who do not receive the drug in Phase I will have the opportunity to enroll in Phase II of the study where everyone will receive the thyroid hormone treatment. If this study finds that patients have improved heart function after treatment with thyroid hormone without unacceptable side effects, this could result in a new treatment for patients with heart failure.

Conditions Studied

Heart Failure

Interventions

  • OTHER Control Group
  • DRUG Thyroid hormone T3

Study Locations (2)

Georgia

  • Emory University Hospital (EUH) - Atlanta
  • Emory University Hospital Clinical Research Network - Atlanta

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2022-12-02
Est. Completion 2026-05
Phase Phase 1

Sponsor

Emory University

1,208 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05384847

The ClinicalTrials.gov registry entry for NCT05384847 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Control Group is the first listed.

NCT05384847 reports 2 study locations spanning 1 distinct geographic area - top geographies include Georgia.

Frequently Asked Questions

What is clinical trial NCT05384847 about?

NCT05384847 is a clinical study titled "Effects of Triiodothyronine (T3) in Ischemic Heart Failure". This study aims to determine whether giving triiodothyronine (T3), a thyroid hormone, is safe and helps improve symptoms and signs of heart failure. The study is divided into 2 phases. In the first phase, participants have a 50-50 chance of receiving the study drug. Participants who are enrolled to...

What is the current status of trial NCT05384847?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2022-12-02. Estimated completion is 2026-05.

What conditions does trial NCT05384847 study?

This clinical trial studies the following conditions: Heart Failure.

What interventions are being tested in trial NCT05384847?

The interventions under investigation include: Control Group (OTHER), Thyroid hormone T3 (DRUG).

Who is sponsoring clinical trial NCT05384847?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05384847 being conducted?

This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Heart Failure

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.